All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 68 points (0.4%) at 17,604 as of Tuesday, March 29, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,037 issues advancing vs. 895 declining with 166 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.4%. Top gainers within the industry include

Alkermes

(

ALKS

), up 6.4%,

Mylan

(

MYL

), up 2.5%,

Sanofi

(

SNY

), up 2.4%,

Illumina

(

ILMN

), up 2.1% and

Teva Pharmaceutical Industries

(

TEVA

), up 1.8%. On the negative front, top decliners within the industry include

Celgene

(

CELG

), down 1.1%, and

Gilead

(

GILD

), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Bristol-Myers Squibb Company

(

BMY

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $0.89 (1.4%) to $63.66 on light volume. Thus far, 2.0 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.3 million shares. The stock has ranged in price between $62.33-$63.73 after having opened the day at $62.45 as compared to the previous trading day's close of $62.77.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $104.4 billion and is part of the health care sector. Shares are down 8.8% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Bristol-Myers Squibb Company Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

AbbVie

(

ABBV

) is up $0.32 (0.6%) to $56.43 on light volume. Thus far, 1.9 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $55.22-$56.49 after having opened the day at $56.09 as compared to the previous trading day's close of $56.11.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $90.4 billion and is part of the health care sector. Shares are down 5.3% year-to-date as of the close of trading on Monday. Currently there are 10 analysts who rate AbbVie a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Merck

(

MRK

) is up $0.44 (0.8%) to $53.27 on light volume. Thus far, 3.0 million shares of Merck exchanged hands as compared to its average daily volume of 11.4 million shares. The stock has ranged in price between $52.57-$53.32 after having opened the day at $52.91 as compared to the previous trading day's close of $52.83.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $147.3 billion and is part of the health care sector. Shares are up 0.0% year-to-date as of the close of trading on Monday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).